Full Press Release Details
BridgeBio Pharma Reports Fourth Quarter And Full Year 2024 Financial Results And Commercial Update.
BBIO
BridgeBio Pharma Reports Fourth Quarter And Full Year 2024 Financial Results And Commercial Update
Key Takeaway: BridgeBio Pharma Reports Fourth Quarter And Full Year 2024 Financial Results And Commercial Update
Price reaction · baseline $36.29 (2025-02-19 close) · hit after-hours · 1 other BBIO headline(s) in the window, move may be shared
day 0 close
+1.4%
day 1
+1.5%
day 3
-5.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis